Ascendis Pharma A/S
ASND · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 20-F · SEC EDGAR
- Reporting
- EUR
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Ascendis Pharma A/S at a glance
In FY2025, Ascendis Pharma A/S reported revenue of EUR 720 mn, EBITDA of EUR -119 mn, EBITDA margin of -16.5%.
| EUR mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 364 | 720 | |||
| EBITDA | -261 | -119 | |||
| EBITDA margin | -71.8% | -16.5% | |||
| ROIC | -213.7% | -161.6% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas